Critical Review On Depression PSY 630 Psychopharmacology Ash

Critical Review On Depression PSY 630 Psychopharmacology Ashford University May 12, 2018

Depression is a complex mental health disorder linked to chemical imbalances in the brain, specifically involving neurotransmitters and receptor activity. Neurotransmitter theories suggest that deficiencies in key chemicals such as serotonin, norepinephrine, and dopamine contribute significantly to the development of depression. These imbalances can be influenced by biological, psychological, and social factors, with the brain's chemical communication pathways playing a pivotal role in mood regulation and behavioral outcomes (Lam, 2018).

The brain utilizes neurons to communicate via neurotransmitters that are released into synapses, facilitating signal transmission across neural pathways. The dysregulation of these neurotransmitters is commonly associated with depressive symptoms. For example, serotonin influences various bodily functions including sleep, mood, appetite, and sexual behavior. A decrease in serotonin levels is correlated with symptoms such as persistent sadness, hopelessness, irritability, and, in severe cases, suicidal ideation. Serotonin reuptake inhibitors such as Prozac and Paxil are commonly prescribed to increase extracellular serotonin levels, helping to alleviate depressive symptoms (Lam, 2018).

Norepinephrine, another crucial neurotransmitter, is linked to alertness and the body’s response to stress. A deficiency in norepinephrine often results in depressed mood, fatigue, and difficulty concentrating. Individuals with recurrent depression tend to exhibit reduced norepinephrine activity, which hampers their stress response mechanism. It is noteworthy that stress can influence norepinephrine levels dynamically, with stress-induced norepinephrine surges contributing to anxiety and mood dysregulation when the system fails to respond appropriately (Beck & Alford, 2009).

Dopamine plays a crucial role in the brain's reward system, motivating individuals to pursue pleasurable activities. Reduced dopamine levels are associated with anhedonia, a core symptom of depression characterized by diminished interest or pleasure in activities formerly enjoyed. Low dopamine activity may be reflected in reduced motivation, fatigue, and weight fluctuations. Agents like bupropion (Wellbutrin) are used to increase dopamine transmission, providing therapeutic benefits for depression with prominent anhedonia (Beck & Alford, 2009).

Receptor theories offer additional insights into depression's neurobiological mechanisms. During depressive episodes, there is evidence of receptor hypersensitivity or sub-sensitivity at pre- and post-synaptic sites, notably involving beta-adrenergic receptors. These alterations influence neurotransmitter transmission efficiency, further exacerbating the imbalance. Dysregulation at receptor sites impairs communication between neurons, contributing to the persistence of depressive symptoms (Wasserman, 2011).

Research indicates that neurotransmitter imbalances are also associated with changes in brain structure and function. A notable study utilizing UK Biobank data revealed alterations in white matter integrity among depressed individuals, characterized by reduced white matter quality. As white matter facilitates communication between different brain regions, its deterioration may underlie cognitive and emotional deficits observed in depression. Neuroplastic responses include cortical thickening, which might serve as a compensatory mechanism to reduce symptom severity, though overall structural disintegration impairs neural connectivity (Wasserman, 2011).

Behaviorally, depression manifests through a spectrum of changes, including irritability, agitation, social withdrawal, and lack of motivation. Neurobiological changes, such as white matter reduction and cortical modifications, underpin these behavioral alterations. Symptoms like fatigue, weight fluctuations, and concentration difficulties are linked with neurotransmitter disruptions, emphasizing the complex interplay between biochemical and structural brain factors (Lam, 2018).

In conclusion, depression results from a multifaceted interaction of neurotransmitter deficiencies, receptor sensitivities, and structural brain changes. Understanding these neurochemical and anatomical components enhances the development of targeted pharmacological interventions, such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors, which aim to correct specific neurotransmitter imbalances. Continued research into the neurobiology of depression offers hope for more effective treatments tailored to individual neurochemical and structural profiles, ultimately improving patient outcomes (CDC, n.d.).

References

• Beck, A. T., & Alford, B. A. (2009). Depression: Causes and Treatment. University of Pennsylvania Press.
• Centers for Disease Control and Prevention (CDC). (n.d.). Mental Health Conditions: Depression and Anxiety.
• Lam, R. W. (2018). Depression. Oxford: Oxford University Press.
• Wasserman, D. (2011). Depression. Oxford: Oxford University Press.
• Harvard Medical School. (2018). Brain science and depression. Harvard Health Publishing.
• Mayberg, H. S. (2003). Modulating neural circuits: Brain activity and depression. The Journal of Clinical Psychiatry, 64(3), 28-33.
• Oquendo, M. A., & Mann, J. J. (2014). The neurobiology of depression. The Psychiatric Clinics of North America, 37(1), 111-125.
• Nutt, D. J. (2008). The neurobiology of depression: An update. Journal of Neural Transmission, 115(11), 1505–Beck, A. T., & Steer, R. A. (1987). Internal consistency of the Beck Depression Inventory in psychiatric outpatients. Journal of Clinical Psychology, 43(2), 199-223.
• Mayberg, H. S. (2005). Deep brain stimulation for treatment-resistant depression. Neuron, 45(5), 651-660.
• van Praag, H., Christie, B. R., Sejnowski, T. J., & Gage, F. H. (2002). Exercise enhances neurogenesis and synaptic plasticity in the adult brain. Nature Reviews Neuroscience, 3(3), 175-184.